T Holler
Overview
Explore the profile of T Holler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
266
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Keyver-Paik M, Abramian A, Domrose C, Doser A, Holler T, Friedrich M, et al.
J Cancer Res Clin Oncol
. 2015 Oct;
142(2):481-7.
PMID: 26498774
Introduction: Late-stage ovarian cancer patient's survival depends on complete cytoreduction and chemotherapy. Complete cytoreduction is more often achieved in institutions with a case volume of >20 cases per year. The...
2.
Voth H, Landsberg J, Hinz T, Wenzel J, Bieber T, Reinhard G, et al.
J Eur Acad Dermatol Venereol
. 2011 Jun;
25(12):1385-91.
PMID: 21645124
Fibrosarcomatous transformation represents a rare event in dermatofibrosarcoma protuberans (DFSP) with unpredictable biological behaviour. No guidelines for the adequate treatment of patients with this rare neoplasm have been published. Herein,...
3.
Gambhir L, Holler T, Muller M, Schott G, Vogt H, Detlefsen B, et al.
J Urol
. 2008 Feb;
179(4):1539-43.
PMID: 18295266
Purpose: We sought to identify causative nongenetic and genetic risk factors for the bladder exstrophy-epispadias complex. Materials And Methods: A total of 237 families with the bladder exstrophy-epispadias complex were...
4.
Schurmann R, Holler T, Benda N
Climacteric
. 2004 Oct;
7(2):189-96.
PMID: 15497908
Method: A randomized, placebo-controlled trial was conducted to evaluate the safety and efficacy of drospirenone (1, 2 or 3 mg) combined with estradiol (1 mg) in the treatment of climacteric...
5.
Wicke C, Teichmann R, Holler T, Rehder F, Becker H
Chirurg
. 2004 May;
75(9):907-15.
PMID: 15168029
Background: Clinical pathways are a new initiative intended to reduce costs while maintaining or even improving the quality of care. Based on treatment guidelines, patient pathways display an optimal sequence...
6.
Endrikat J, Klipping C, Gerlinger C, Ruebig A, Schmidt W, Holler T, et al.
Contraception
. 2001 Dec;
64(4):235-41.
PMID: 11747873
In this double-blind study we compared the influence of two oral contraceptives, a 23-day regimen with 20 microg ethinyl estradiol and 75 microg gestodene (23-day 20/75) and a 21-day regimen...
7.
Hagen S, Domagala J, Gajda C, Lovdahl M, Tait B, Wise E, et al.
J Med Chem
. 2001 Jun;
44(14):2319-32.
PMID: 11428926
Due largely to the emergence of multi-drug-resistant HIV strains, the development of new HIV protease inhibitors remains a high priority for the pharmaceutical industry. Toward this end, we previously identified...
8.
Schmolling J, Renke K, Richter O, Pfeiffer K, Schlebusch H, Holler T
Ther Drug Monit
. 2000 Oct;
22(5):582-8.
PMID: 11034264
Clinical observations suggest that flecainide might pass the placenta more easily than digoxin, and that its transfer is less disturbed in case of hydrops fetalis than that of digoxin. The...
9.
Willinek W, Ludwig M, Lennarz M, Holler T, Stumpe K
J Hypertens
. 2000 Apr;
18(4):425-30.
PMID: 10779093
Objective: Moderate hyperhomocysteinaemia is common in the general population and has been linked with systemic atherosclerotic vascular disease. We studied the relation of sonographically determined carotid intima-media wall thickness to...
10.
Boyer F, Vara Prasad J, Domagala J, Ellsworth E, Gajda C, Hagen S, et al.
J Med Chem
. 2000 Mar;
43(5):843-58.
PMID: 10715152
On the basis of previous SAR findings and molecular modeling studies, a series of compounds were synthesized which possessed various sulfonyl moieties substituted at the 4-position of the C-3 phenyl...